Contributed by:

PharmaVOICE Staff

NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.

Industry at Large

PV0316_endaEndo Launches Scholarship Program

New initiative honoring the Qualitest name is designed to reward students in the Huntsville, Ala., region pursuing higher education.

Endo International has funded a new scholarship program designed to make higher education more accessible for the next generation of Huntsville, Ala., leaders. The newly created Qualitest Scholarship Program is a $50,000 education initiative that reflects Endo’s dedication to the legacy of Qualitest, which was recently renamed Par Pharmaceutical as a result of Endo’s acquisition of Par Pharmaceutical Holdings.

AstraZeneca HealthCare Foundation Awards $2 Million for Heart Health

Eleven innovative community-based heart health programs with tailored approaches to prevent and control heart disease have received grants totaling $1.9 million from AstraZeneca HealthCare Foundation’s Connections for Cardiovascular Health program. The Foundation is awarding grants to nonprofit organizations across the country that are conducting health programs for at-risk groups, from teenagers to Latinos and African American women.

Since 2010, the Connections for Cardiovascular Health program has awarded more than $19 million in grants to 47 organizations nationwide.

Bristol-Myers Squibb Foundation Awards $11.5 Million for Lung and Skin Cancer Screening

PV0316_SpecialtyDrugsThe Bristol-Myers Squibb Foundation has announced eight grants totaling nearly $11.5 million that will help make lung and skin cancer screening programs, care and patient support more accessible to underserved populations. The goal is to develop, validate, and sustain models that deliver equitable and optimal outcomes. The grants were awarded through the Foundation’s Bridging Cancer Care and Specialty Care for Vulnerable Populations initiatives.

PharmaVOICE@Industry Events

Innovators Turn Out for 23rd Annual BioNJ Gala
The N.J. life-sciences community came out for the 23rd Annual BioNJ Annual Gateway Gala, Dinner Meeting & Innovation Celebration that took place on February 4. The inspirational evening celebrated the unprecedented medical innovation in the form of FDA drug approvals coming from the Garden State.
Dedicated to “Patients… Because they just can’t wait,” nearly 700 biotechnology and pharmaceutical professionals, academic leaders, service providers, and government officials honored 16 innovator companies with a footprint in New Jersey that were responsible for 27 new drug approvals granted by the FDA in 2015.

“We are so proud of New Jersey’s robust life-sciences ecosystem that was responsible for more than 50% of all new FDA drug approvals in 2015, reinforcing the fact that New Jersey is the drug development capital of the world,” says BioNJ CEO and President Debbie Hart. “Our members are helping patients live longer, better lives while lessening the burden of illness and disease on society. We are pleased to celebrate their important work and dedication in this way.”

The evening included the presentation of the ninth annual Dr. Sol J. Barer Award for Vision, Innovation and Leadership to Dr. Clive Meanwell, founder and CEO of The Medicines Company. Since its inception in 1996, Dr. Meanwell has carefully guided The Medicines Company to the innovative institution it is today — known for developing products that industry experts have dubbed “game-changers” in treating cardiovascular disease, infectious disease, and sedation. In 2015 alone, The Medicines Company had four U.S. approvals and four in the EU.

For more information about BioNJ and to view the video of Dr. Meanwell, please visit bionj.org.


Posted in:

Post a Comment

You must be logged in to post a Comment.